INVESTOR DUE DILIGENCE & ASSET DEVELOPMENT
Clinical diligence and development architecture for investors, boards and companies preparing capital or partnering decisions.
THE INVESTMENT QUESTION
Clarify what the asset must prove and which assumptions carry the valuation.
Separate biological uncertainty from design, regulatory and operating risk.
Sequence evidence, milestones and funding around observable value creation.
OUR DILIGENCE PATHWAY
Test the scientific premise and development assumptions.
Build the clinical, regulatory, payer and execution risk map.
Challenge endpoints, comparators, feasibility and timing.
Align evidence generation with value-inflection points.
Translate the plan into capital and partnering logic.
Define gates, controls and escalation for execution.
WHAT WE OFTEN CHANGE FIRST
Make hidden assumptions explicit and connect them to mitigation and decision gates.
Test whether the programme is being designed against the market it will actually face.
Stop funding chronology from dictating scientific sequence.
Turn calendar events into evidence-based continue, adapt or stop decisions.
Make recommendations executable and governable after the transaction.
NEXT DISCUSSION
Copyright © 2026 Manolo Beelke & Partners. All rights reserved.
